{"denoms":[{"counts":[{"groupId":"BG000","value":"6"}],"units":"Participants"}],"groups":[{"description":"Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12.\n\nParticipants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12.","id":"BG000","title":"Carfilzomib Plus Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.2","value":"62.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"18 - 64 years"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"65 - 74 years"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"≥ 75 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"White"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"0 (Fully active)"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"1 (Restricted but ambulatory)"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"2 (Ambulatory but unable to work)"}]}],"description":"A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction;\n\n1. = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature;\n2. = Ambulatory and capable of all self-care, unable to carry out any work activities. Up and about \\> 50% of waking hours;\n3. = Capable of only limited self-care, confined to bed or chair \\> 50% of waking hours;\n4. = Completely disabled, confined to bed or chair;\n5. = Dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Scale","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"1 prior regimen"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"2 prior regimens"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"3 prior regimens"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of Prior Treatment Regimens","unitOfMeasure":"Participants"}],"populationDescription":"The full analysis set includes all enrolled participants who received at least 1 dose of any study treatment (ie, carfilzomib or dexamethasone)."}